Company research
Surrozen, Inc./DE
CIK 1824893Updated Sep 27, 2026
SecuritySRZN · NASDAQ · equity
Name history
Consonance-HFW Acquisition Corp. · through Aug 11, 2021
SRZN price & chart
Loading TradingView…
NASDAQ:SRZN on TradingView ↗About the company
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 98,726,000Source | 48,467,000Source | 46,080,000Source | 89,435,000Source |
| Property, Plant and Equipment, NetUSD | 433,000Source | 562,000Source | 1,969,000Source | 3,630,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 89,245,000Source | 34,565,000Source | 36,043,000Source | 24,690,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 2,039,000Source | 2,152,000Source | 1,978,000Source |
| Assets, CurrentUSD | 91,559,000Source | 38,932,000Source | 41,132,000Source | 81,305,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,106,000Source | 1,826,000Source | 2,937,000Source | 3,489,000Source |
| Operating Lease, Right-of-Use AssetUSD | 6,000,000Source | 7,801,000Source | 1,889,000Source | 3,268,000Source |
| Other Assets, NoncurrentUSD | 46,000Source | 331,000Source | 402,000Source | 827,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 286,488,000Source | 69,847,000Source | 8,145,000Source | 13,434,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 0Source | 0Source | 3,000Source |
| Additional Paid in CapitalUSD | 339,522,000Source | 263,879,000Source | 259,630,000Source | 254,892,000Source |
| Retained Earnings (Accumulated Deficit)USD | -527,285,000Source | -285,259,000Source | -221,695,000Source | -178,653,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | — | 0Source | -241,000Source |
| Stockholders' Equity Attributable to ParentUSD | -187,762,000Source | -21,380,000Source | 37,935,000Source | 76,001,000Source |
| Liabilities and EquityUSD | 98,726,000Source | 48,467,000Source | 46,080,000Source | 89,435,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,930,000Source | 7,315,000Source | 7,148,000Source | 9,732,000Source |
| Operating Lease, Liability, CurrentUSD | 1,290,000Source | 1,829,000Source | 2,497,000Source | 2,226,000Source |
| Accounts Payable, CurrentUSD | 728,000Source | 306,000Source | 525,000Source | 658,000Source |
| Operating Lease, Liability, NoncurrentUSD | 5,349,000Source | 6,640,000Source | 882,000Source | 3,376,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,912,000Source | 5,180,000Source | 4,126,000Source | 6,848,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 75,800,000Source |
| Deferred Tax Liabilities, NetUSD | 1,680,000Source | 1,715,000Source | 449,000Source | 781,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -242,026,000Source | -63,564,000Source | -43,042,000Source | -36,004,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,835,000Source | 4,114,000Source | 4,372,000Source | 4,517,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -2,039,000Source | 502,000Source | 0Source | 1,978,000Source |
| Increase (Decrease) in Accounts PayableUSD | 142,000Source | -228,000Source | -133,000Source | -2,038,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -30,244,000Source | -17,628,000Source | -40,363,000Source | -44,145,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -128,000Source | -26,000Source | 51,723,000Source | 38,309,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 128,000Source | 26,000Source | 398,000Source | 728,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 0Source | 2,607,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 85,052,000Source | 16,176,000Source | 276,000Source | -2,565,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 54,680,000Source | -1,478,000Source | 11,636,000Source | -8,401,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 89,933,000Source | 35,253,000Source | 36,731,000Source | 25,095,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 75,800,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | -113,000Source | 174,000Source | — |
| Gain (Loss) on Termination of LeaseUSD | — | 400,000Source | — | — |
| General and Administrative ExpenseUSD | 16,204,000Source | 15,062,000Source | 15,798,000Source | 19,826,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | 3,020,000Source | 1,693,000Source | 2,340,000Source | 781,000Source |
| Net Income (Loss) Attributable to ParentUSD | -242,026,000Source | -63,564,000Source | -43,042,000Source | -36,004,000Source |
| Operating ExpensesUSD | 45,569,000Source | 36,194,000Source | 45,780,000Source | 56,839,000Source |
| Operating Lease, ExpenseUSD | 2,400,000Source | 1,800,000Source | 1,600,000Source | 1,900,000Source |
| Other Nonoperating Income (Expense)USD | -26,312,000Source | -19,321,000Source | 398,000Source | 7,554,000Source |
| Payments for Repurchase of WarrantsUSD | — | — | 0Source | 85,000Source |
| Proceeds from Issuance of Common StockUSD | 74,702,000Source | 16,043,000Source | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | 87,000Source | 39,000Source | 3,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,477,000Source | 10,655,000Source | 0Source | 12,500,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | 700,000Source | 700,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 0Source | 241,000Source | -122,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 3,477,000Source | 10,655,000Source | — | — |
| Operating Income (Loss)USD | -42,092,000Source | -25,539,000Source | -45,780,000Source | -44,339,000Source |
| Other Nonoperating Income (Expense)USD | -26,312,000Source | -19,321,000Source | 398,000Source | 7,554,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -242,028,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -242,026,000Source | -63,564,000Source | -43,042,000Source | -36,004,000Source |
| Earnings Per Share, BasicUSD per share | -32.37Source | -21.67Source | -21.33Source | -1.04Source |
| Earnings Per Share, DilutedUSD per share | -32.37Source | -21.67Source | -21.33Source | -1.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 7,478Source | 2,933Source | 2,018Source | 34,722Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 7,478Source | 2,933Source | 2,018Source | 34,722Source |
| Additional Financial Items | ||||
| Business Combination, Acquisition Related CostsUSD | — | — | — | 0Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 537,000Source | 1,442,000Source | 1,911,000Source | 1,955,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 0Source | -113,000Source | 174,000Source | — |
| General and Administrative ExpenseUSD | 16,204,000Source | 15,062,000Source | 15,798,000Source | 19,826,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -241,979,000Source | — | — | — |
| Investment Income, InterestUSD | 3,020,000Source | 1,693,000Source | 2,340,000Source | 781,000Source |
| Operating ExpensesUSD | 45,569,000Source | 36,194,000Source | 45,780,000Source | 56,839,000Source |
| Operating Lease, ExpenseUSD | 2,400,000Source | 1,800,000Source | 1,600,000Source | 1,900,000Source |
| Other ExpensesUSD | 2,800,000Source | — | — | — |
| Research and Development ExpenseUSD | 29,365,000Source | 21,132,000Source | 27,230,000Source | 37,013,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 3,477,000Source | 10,655,000Source | 0Source | 12,500,000Source |
Filing attachments
srzn-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 srzn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026 Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027 U.S. Patent Trial and Appeal Board denies institution of post-grant review petition challenging Surrozen patent SOUTH SAN …
Read attachment ↗srzn-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 srzn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update On track to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Well-capitalized with $106.9 million in cash and cash equivalents as of March 31, 2026 SOUTH SAN FRANCISCO, Calif., May 6, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering tar…
Read attachment ↗srzn-ex99_1.htm · 8-K · 2026-03-23
EX-99.1 2 srzn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Str…
Read attachment ↗